Justus Baumgarten

Frankfurt Am Main, HE 60596, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Fifty shades of green and blue: autopsy findings after administration of xenobiotics.

Fifty shades of green and blue: autopsy findings after administration of xenobiotics.

Journal: Forensic science, medicine, and pathology
Published: October 14, 2024

Interobserver Agreement in Ultrasound Risk Stratification Systems for Thyroid Nodules on Static Images Versus Cine-Loop Video Sequences.

Interobserver Agreement in Ultrasound Risk Stratification Systems for Thyroid Nodules on Static Images Versus Cine-Loop Video Sequences.

Journal: Diagnostics (Basel, Switzerland)
Published: August 18, 2024

Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET/CT.

Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET/CT.

Journal: Cancers
Published: July 11, 2023

Thyroid papillary cancer elements arising from struma ovarii with benign peritoneal strumosis: Utility of iodine-123 imaging in diagnostics and treatment planning.

Thyroid papillary cancer elements arising from struma ovarii with benign peritoneal strumosis: Utility of iodine-123 imaging in diagnostics and treatment planning.

Journal: Clinical case reports
Published: January 16, 2023

Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions.

Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions.

Journal: Cancers
Published: November 11, 2022

Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer.

Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging
Published: October 07, 2022

Radiofrequency ablation of benign thyroid nodules

Radiofrequency ablation of benign thyroid nodules

Journal: Laryngo- rhino- otologie
Published: June 23, 2022

Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer.

Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer.

Journal: Current oncology (Toronto, Ont.)
Published: March 07, 2022

Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios

Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios

Journal: Nuklearmedizin. Nuclear medicine
Published: February 16, 2022

Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride.

Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride.

Journal: Cancers
Published: December 13, 2021

High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis.

High overall mortality of Mycobacterium genavense infections and impact of antimycobacterial therapy: Systematic review and individual patient data meta-analysis.

Journal: The Journal of infection
Published: July 29, 2021

Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement.

Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement.

Journal: Cancers
Published: June 30, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026